Full-Time

Senior/Principal Scientist

Lung Cancer Research

Posted on 2/2/2024

23andMe

23andMe

501-1,000 employees

Direct-to-consumer DNA testing services

Compensation Overview

$160k - $240k/yr

Senior

Sunnyvale, CA, USA

Requires onsite presence in Sunnyvale, CA for a minimum of 3 days per week.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Science
Data Analysis
Requirements
  • PhD or MD with 5 years of research experience in oncology post graduate degree
  • Ability to be able to provide direction for a large scale lung cancer cohort study while incorporating strategic scientific and business goals
  • Expertise in clinical research, longitudinal research, epidemiological modeling, or computational biology preferred
  • Expertise or hands-on experience with 'big data' and/or natural history data applied to oncology
  • Ability to represent the company and the lung cancer cohort findings at appropriate scientific, non-scientific, and other professional meetings
  • Ability to establish and maintain key relationships with internal and external stakeholders, including patient advocacy groups and other community-based disease focused organizations
  • Ability to lead directly and by influence, including strong problem solving and conflict resolution skills
  • Exceptional communication skills across many mediums. Demonstrated ability to communicate clearly, concisely, and empathetically to both scientific and non-scientific audiences
Responsibilities
  • provide scientific and strategic leadership for research initiatives involving our lung cancer cohort
  • responsible for the scientific success of the lung cancer research program
  • developing and executing a research plan to achieve the programmatic aims
  • soliciting input from key internal and external stakeholders
  • tracking project goals
  • implementing an analysis plan
  • collaboration with an external study sponsor and their advisors

23andMe offers direct-to-consumer DNA testing that provides individuals with insights into their ancestry, genetic traits, and potential health risks. Customers purchase a DNA testing kit, send in a saliva sample, and receive personalized genetic reports based on the analysis of their DNA. This service appeals to a wide range of people, from those curious about their family history to those wanting to understand their health predispositions. Unlike many competitors, 23andMe not only sells DNA kits but also offers subscription services for ongoing updates and insights based on new genetic research. Additionally, the company utilizes its large genetic database for research collaborations, which can lead to further revenue through partnerships with research institutions and pharmaceutical companies. The goal of 23andMe is to empower individuals with knowledge about their genetics while contributing to advancements in genetic research.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

2006

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing interest in personalized medicine boosts demand for 23andMe's genetic testing services.
  • Advancements in AI enhance 23andMe's ability to provide detailed genetic insights.
  • Partnerships with telehealth providers offer opportunities for comprehensive health solutions.

What critics are saying

  • Bankruptcy proceedings may lead to mishandling of sensitive genetic data.
  • Leadership changes could result in strategic instability for 23andMe.
  • Increased scrutiny on data security poses regulatory challenges for the company.

What makes 23andMe unique

  • 23andMe offers direct-to-consumer DNA testing, a pioneering service in genetics.
  • The company provides personalized genetic reports, enhancing consumer understanding of their DNA.
  • 23andMe collaborates with research institutions, leveraging its extensive genetic database.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health, vision, & dental plans

Family planning, support, & leave for parents

Mental healthcare

Student loan assistance

Volunteer time off

Dog friendly office

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

3%

2 year growth

2%
PYMNTS
Apr 17th, 2025
23Andme’S Data Security Catches Attention Of House Gop

A trio of lawmakers want answers from 23andMe about the security of its customer data. In a letter to the bankrupt genetic testing service Thursday (April 17), members of the House Committee on Energy and Congress expressed concerns that this data could be compromised following a sale. The letter from Rep. Brett Guthrie of Kentucky, Rep. Gus Bilirakis of Florida and Rep. Gary Palmer of Alabama said that generally speaking, direct-to-consumer firms such as 23andMe are not covered by the Health Insurance Portability and Accountability Act (HIPAA)

Insolvency Guardian
Apr 13th, 2025
DNA testing firm 23andMe files for bankruptcy as demand dries up - Reuters

DNA testing firm 23andme files for bankruptcy as demand dries up - reuters.

VPNMentor
Apr 7th, 2025
openSNP Shutters Over Privacy and Authoritarianism Concerns

The decision comes as 23andMe, a major source of user-submitted genetic data for openSNP, faces bankruptcy and a potential selloff of user data.

Republican Investor
Mar 26th, 2025
23andMe bankruptcy: Will your private data be protected?

Genetic testing company 23andMe is seeking a new owner as part of its Chapter 11 bankruptcy protection proceedings.

Fox News
Mar 25th, 2025
Protect your genetic data: Urgent steps after 23andMe bankruptcy

The genetic testing company 23andMe, once a pioneer in consumer DNA testing, has filed for Chapter 11 bankruptcy amid financial struggles, a leadership shakeup and growing concerns about the security of its customers' genetic data.

INACTIVE